Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4420 Nab-paclitaxel plus bevacizumab for patients with previously treated, metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A multicentre, open-label, phase II trial

Introduction: No standard therapies beyond first line are established for advanced EP-NECs. Paclitaxel is also active in NECs however there is no data on the role of nab-paclitaxel.

Conference:

Presenting Author: Zhang P

Authors: Zhang P, Li S, Li J, Shen L, Lu M,

Keywords: extrapulmonary neuroendocrine carcinoma, nab-paclitaxel, bevacizumab,

#4392 Updated results of first-line chemotherapy combined with an immune checkpoint inhibitor for advanced extrapulmonary neuroendocrine carcinoma: A single arm, phase II study

Introduction: NEC is a rare, aggressive cancer with limited response to standard first-line chemo (etoposide + cisplatin/carboplatin, EP/EC).

Conference:

Presenting Author:

Authors: Cao D, Li X, Li R, Wang X, Yang Y,

Keywords: neuroendocrine carcinoma, First-line, chemotherapy, camrelizumab,

#4019 Updated data from a phase I trial of the DLL3/CD3 IgG-like T-cell engager BI 764532 in patients (pts) with DLL3-positive (+) tumors: Focus on extrapulmonary neuroendocrine carcinomas (epNECs)

Introduction: DLL3 is expressed on several cancers including epNECs. BI 764532 is a DLL3/CD3 IgG-like T-cell engager. NCT04429087 is a Phase I trial of BI 764532 in pts with locally advanced/metastatic DLL3+ small-cell lung cancer, epNEC or large-cell neuroendocrine lung carcinoma. Here we focus on pts with epNEC.

Conference:

Presenting Author: Capdevila J

Authors: Capdevila J, Gambardella V, Kuboki Y, Alese O, Morgensztern D,

Keywords: DLL3, NEC, T-cell engager,

#4015 Responses to Cabozantinib plus Atezolizumab in a wide population of advanced and progressive neuroendocrine neoplasms (NENs): A prospective multi-cohort basket phase II Trial (CABATEN / GETNE-T1914)

Introduction: Angiogenesis plays a key role in development and progression of NENs and synergism has been observed when combined with immune-checkpoint inhibitors in other tumors.

Conference:

Presenting Author: Molina-Cerrillo J

Authors: Molina-Cerrillo J, Grande E, Benavent M, Garcia-Carbonero R, Teule A,

Keywords: neuroendocrine neoplasm, Cabozantinib, Atezolizumab, CABATEN, prospective multi-cohort Basket Phase II Trial,

#4005 Camrelizumab plus chemotherapy as first-line treatment for advanced extrapulmonary neuroendocrine carcinoma: An investigator-initiated phase 2 study (CAMEC trial)

Introduction: The standard chemotherapy composed of etoposide and cisplatin/carboplatin (EP/EC) for extra-pulmonary neuroendocrine carcinoma (NEC) is of limited efficacy.

Conference:

Presenting Author:

Authors: Li X, Li R, Cheng K, Cao D,

Keywords: extra-pulmonary NEC, first-line, immune checkpoint inhibitor, chemotherapy,